Eli Lillys retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, remains in Phase 3 TRIUMPH trials as of mid-2026, with NDA submission projected no earlier than Q4 2026
That's why stumbling upon L-Carnitine shots felt like finding a hidden gem
Yet, most patients find the treatment approachable when factoring in health benefits and available payment tools
Meanwhile, adoption of existing medications for SUD is very low, particularly for AUD: AUD is a leading cause of mortality and morbidity, but compared with other chronic diseases such as cancers, hypertension, diabetes and depression, there is a very small number of US Food and Drug administration (FDA)-approved medications for AUD (acamprosate, disulfiram and naltrexone)
Its taken once a week and was approved by the FDA in 2017 to treat type 2 diabetes
We meticulously consider each cells C rating and strategically configure them to achieve the optimal balance between power delivery, capacity, and longevity for your unique application
